Nasdaq: AVLN · Listed Apr 30, 2026
Avalyn Pharma IPO
IPO price
$18.00
Avalyn Pharma (AVLN) priced its IPO at $18.00 a share and has traded on Nasdaq since Apr 30, 2026.
AVLN today$28.09+56.06%since IPO15-min delayed · as of 4:20:48 PM EST on Nov 18, 2026
See the AVLN quoteFirst trading day · Apr 30, 2026
- IPO price
- $18.00
- the top of the range of $16 to $18
- First trade
- $26.00
- +44.44% from the IPO price
- First-day last trade
- $29.50
- +63.89% from the IPO price, regular session
- Raise
- $300M
- before the underwriters' option
These numbers are from the first trading day, Apr 30, 2026.
How AVLN did against the market
AVLN against the market, from its first trade at 12:20 ET to the last trade of the session.
- AVLN from its first trade
- +13.46%
- Against the market (QQQ)
- +12.9 pts
AVLN rose 13.5% from its first trade to the last trade of the session. That is 12.9 points better than the market.
Same-day moves do not show that AVLN caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
AVLN against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
AVLN against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Avalyn Pharma '26 | $300M | +44.44% | +63.89% | +51.39% | +56.50% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Avalyn Pharma IPO offers 16.67M shares to raise $300M, before any underwriters' option.
- Expected price range
- $16 to $18
- IPO price
- $18.00
- Shares offered
- 16.67M
- Money raised
- $300M
- Listing date
- Apr 30, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Avalyn Pharma$300M
Where AVLN ranks
Avalyn Pharma's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- AVLN$1.23B
AVLN news
The latest news and headlines about Avalyn Pharma (AVLN).
- Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026positiveGlobeNewswire Inc.· Aug 24, 2026
- Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary FibrosispositiveGlobeNewswire Inc.· Jun 17, 2026
- Avalyn Reports First Quarter 2026 Financial Results and Recent Business HighlightspositiveGlobeNewswire Inc.· Jun 3, 2026
Filings and the company
What Avalyn Pharma has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Avalyn Pharma discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Avalyn Pharma Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026.
- Executive compensation changeSep 16, 2026
Under the Company's Non-Employee Director Compensation Policy (the "Compensation Policy"), Dr. Meyer is eligible to receive an annual retainer of $40,000 for serving on the Board. In addition, under the Compensation Policy, on the Effective Date, Dr. Meyer was granted an option to purchase 31,182 shares of the Company's common stock.
- Lease agreementJul 1, 2026
On June 29, 2026, Avalyn Pharma Inc. entered into a First Amendment to the Sublease providing for the lease of approximately 8,774 rentable square feet in the building located at 105 West First Street, Boston, Massachusetts. Pursuant to the Sublease Amendment, the Sublandlord and the Company have agreed to an expansion of the Premises from approximately 8,774 rentable square feet to approximately 13,708 rentable square feet as of the Effective Date. The Company's future minimum lease payments will increase by approximately $924,000 over the remaining lease term.
- Charter amendmentMay 1, 2026
The Company filed an amended and restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware...to, among other things: (i) authorize 700,000,000 shares of common stock, including 500,000,000 shares of voting common stock and 200,000,000 shares of non-voting common stock; (ii) eliminate all references to the previously-existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock.
About Avalyn Pharma
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
- Ticker
- AVLN
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Listed
- Apr 30, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Avalyn Pharma IPO price?
$18.00 a share.
When did Avalyn Pharma go public?
Avalyn Pharma listed on Nasdaq on Apr 30, 2026 under the ticker AVLN.
How much did the Avalyn Pharma IPO raise?
$300M, before any underwriters' option.
How did Avalyn Pharma open on its first day?
AVLN first traded at $26.00, +44.44% from the IPO price of $18.00.
How did AVLN close on its first day?
Its last regular-session trade was $29.50, +63.89% from the IPO price of $18.00.
What was the AVLN first-day trading range?
$26.00 to $30.20 in the regular session.
How many AVLN shares traded on the first day?
6.31M shares in the regular session.
How many shares did Avalyn Pharma sell in its IPO?
16.67M shares.
How did AVLN do against the market on its first day?
AVLN rose 13.5% from its first trade to the last trade of the session. That is 12.9 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is AVLN listed on?
Avalyn Pharma lists on Nasdaq under the ticker AVLN.
Build with Massive
Get the AVLN data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/AVLN/range/5/minute |
| Market cap | /v3/reference/tickers/AVLN |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.